About

EpitogenX: embracing disruption through innovative technologies.

EpitogenX is a forward-thinking biotech with innovative platforms backed by a world-leading scientific team. We strive to improve global healthcare outcomes by offering innovative solutions and affordable products.

EpitogenX Ltd is a holding company aiming to build on the successes of its subsidiary, Vertebrate Antibodies Ltd, to transform the biotech industry by providing high-quality services and products for both the medical and veterinary sectors.

Our EpitoGen® and AI EpitoPrediktTM technologies come together to create a powerful game-changing platform that will transform diagnostics, vaccine design, biotherapeutics, and antibody development.

With the support of Innova Medical Group Inc, we also aim to provide accurate, simple, accessible, and affordable point-of-care testing systems.

Using AI models we offer in silico solutions, validated in vitro and applied to create prototype clinical products using EpitoGen® Technology.

Products developed using this technology are compatible with gold standard lab-based and point-of-care applications (i.e. ELISA, LFA, microfluidics), making them affordable and user friendly.

Our Mission

“To improve life by making accurate and affordable products accessible to community-based healthcare and middle/low-income countries”. At EpitogenX we are very proud of the important role we will play in providing our partners with the means to deliver clinical products.

“Our Vision is to make our game-changing EpitoGen® technology available globally to transform the diagnostic sector”

Operational Team

CHIEF TECHNOLOGY OFFICER

Dr Ayham Alnabulsi

CHIEF EXECUTIVE OFFICER

Dr Abdo Alnabulsi

CHIEF SCIENTIFIC OFFICER

Dr Tiehui Wang

IMMUNOLOGIST

Dr Yehfang Hu

LEAD POC SCIENTIST

Alex Wang

SCIENTIFIC WRITER

Dr Donald Falconer

SENIOR SCIENTIST

Dr Craig Christie

INNOVATION OFFICER

Dr Ralfs Buks

KTP ASSOCIATE - SEROLOGY TEST DEVELOPMENT

Dr Rodanthi Zindrili

CHIEF TECHNOLOGY OFFICER

Dr Ayham Alnabulsi

Strategic visionary and entrepreneur, Ayham Alnabulsi is a co-founder of EpitoGenX and its CTO. Previously, Ayham has also co-founded and led Vertebrate Antibodies and AiBiologics.  Ayham has extensive knowledge in medical genetics, immunology and mathematics, and he is a co-inventor of the game-changer EpitoGen technology.

CHIEF EXECUTIVE OFFICER

Dr Abdo Alnabulsi

Dr. Abdo is a co-founder, director and CEO of EpitogenX Ltd. He previously co-founded AiBiologics and Vertebrate Antibodies, and served as COO and CSO respectively.  Abdo has a unique combination of scientific, financial and commercial expertise with a successful track record in molecular medicine, biomarker discovery, bio-product development, bioinformatics and immunoassays optimisation.

CHIEF SCIENTIFIC OFFICER

Dr Tiehui Wang

Tiehui Wang is a co-founder of the company and brings dynamic technology innovation and insight from his 30 years+ experience in protein engineering. Tiehui has valuable expertise in medical technology innovation as the co-inventor of the game changing EpitoGen® platform. Previously, Tiehui cofounded AiBiologics and served as a Chief Scientist.

IMMUNOLOGIST

Dr Yehfang Hu

Yehfang Hu is an immunologist with a wealth of expertise on veterinary immunology, immunopathology and IVD product development. 

LEAD POC SCIENTIST

Alex Wang

Alex Wang joined the team in 2022 with expertise in the development and optimization of novel point-of-care testing platforms. Alex has a background in medical sciences with experience in biotechnology and medical applications.

SCIENTIFIC WRITER

Dr Donald Falconer

Dr Falconer holds a BSc Honours in Microbiology, MSc in Medicine and therapeutics and PhD in Cognitive Neuroscience. He has been a researcher for nearly 2 decades having worked extensively in both the scientific and social sciences fields. His scientific and academic knowledge is backed up by various publications in scientific papers. He is also a playwright and has authored and produced many plays across the UK.

SENIOR SCIENTIST

Dr Craig Christie

Craig brings a combination of scientific, logistic management and regulatory expertise to EpitoGenx, gained through working in professional environments.

INNOVATION OFFICER

Dr Ralfs Buks

Ralfs brings a unique combination of scientific,Research and Development, management and commercial experience to EpitoGenx. Ralfs is also an expert in pathophysiology with a strong background in clinical assay development.

KTP ASSOCIATE - SEROLOGY TEST DEVELOPMENT

Dr Rodanthi Zindrili

Rodanthi’s expertise includes the creation of data algorithms and specialized bioinformatics pipelines using DNA and protein sequences in order to identify actionable clinical signatures.  Rodanthi will aid in the building a diagnostic serology-based test for Type 1 Diabetes.

Advisory Board

Prof Graeme Murray

Dr Wei Pang

Prof Chris Secombes

BIOTECHNOLOGY OFFICER

Dr Ting-Yu Wang

Prof Mirela Delibegovic

Dr Brittain-Long

Prof Graeme Murray

Professor Murray is Emeritus Regius Professor of Anatomy. He was the lead consultant gastro-intestinal pathologist to NHS Grampian and for the Grampian Biorepository. Professor Murray is an internationally recognised pathologist with specific interests in gastro-intestinal pathology and antibody technologies.

Dr Wei Pang

Wei Pang (Associate Professor, Heriot-Watt University) is a computer scientist who is specialised in Bio-inspired Computing, Machine Learning, and Explainable AI. Wei will apply bio-inspired computing approaches to optimise existing AI tools and develop novel machine learning and data mining algorithms.

Prof Chris Secombes

Professor Secombes (Emeritus Regius Chair of Natural History) is a renowned immunologist with a wealth of expertise on veterinary immunology and immunopathology.
Professor Secombes has made a lasting contribution to the characterisation and elucidation of immune systems in lower vertebrates, influencing in the process disease mitigation and vaccine development.

BIOTECHNOLOGY OFFICER

Dr Ting-Yu Wang

Ting-Yu brings a wealth of expertise in biology, biotechnology,  proteome exploration and metabolomics analyses. Ting-Yu is an expert in investigating proteomics ans metabolics processes using the liquid-chromatography mass spectrometry (LC-MS/MS) platforms. This set of skills are ideal to quantify disease markers and establish accurate diagnostic products

Prof Mirela Delibegovic

Prof Mirela Delibegovic, FRSE, is a Professor in Diabetes Physiology with vast experience in metabolic diseases and cell signalling. She leads many translational projects including drug discovery using bioinformatic and medicinal chemistry approaches, in vitro and in vivo pre-clinical testing, patient derived organoid cultures and patient populations.

Dr Brittain-Long

Dr Brittain-Long is a consultant physician with >25 years of clinical experience. He is a specialist in Infectious Diseases, General Medicine & Acute Medicine with an interest in diagnostics, from the molecular level to direct clinical care. His research & clinical expertise includes tick-borne infections, respiratory viruses, TB and NTM.

Breakthrough Solutions

Serodiagnosis

We offer in silico and in vitro technologies that can accelerate the development of antibody-based assays, improve assay performance, and reduce cost and lead production time. Our novel technology has been created to overcome the main technical issues that have hindered the development of accurate serological tests.

By virtue of the multiplexing capacity of our platform, we can develop break-through diagnostic products. For example, EpitoPrediktTM can isolate allergy associated epitopes, paving the way for the development of effective allergy testing.

Diagnostic Products

EpitoGen® scaffold provides a superior framework to express and display antibody fragments for diagnostic testing. EpitoGen® also increases production yield, improves stability, and reduces cost.

Importantly, the scaffold is engineered to bind preferentially to testing surfaces, ensuring correct orientation of the displayed paratope, consequently improving assay performance.

Vaccine Design

EpitoPrediktTM and EpitoGen® can be used together to accelerate the development of epitope/subunit-based vaccines whilst offering significant safety advantages. EpitoPrediktTM ‘s ability to identify B-cell, CTL and HTL epitopes enhances the efficacy of current vaccine platforms, whilst EpitoGen®‘s multiplexing capacity further improves efficacy and provides an efficient delivery system for vaccine candidates.

Our AI software can also identify immune components that will support mucosal vaccine design (i.e. IgA-rich antigens).

Immunogenicity Profiling

Both platforms (EpitoGen® and EpitoPrediktTM) provide in silico and in vitro screening for potential immunogenic signatures of biological candidates for clinical evaluation.

We can identify immunogenic signatures for the lead candidates to carry forward from preclinical and clinical trials, which improves overall safety and reduces the risk of failure due to immunogenicity issues.

Antibody Bioengineering

Nanobodies can be expressed and displayed on our EpitoGen® scaffolds to improve stability and reduce the cost of production.

Epitope-Based Antibodies

Using our EpitoGen® Scaffolds, multiple immunogen epitopes can be displayed and used to improve the efficiency and quality of antibody development.

Do you have a vaccine, diagnostic, recombinant protein, or antibody project? Are you looking for immunogenicity profiling? Please contact us for details.

Technology

EpitogenX brings together two innovative platforms to create game-changing solutions.

EpitoPrediktTM is an AI software that can accurately identify immunodominant epitopes, a crucial component of diagnostic, prophylactic and immunotherapeutic vaccines.

The software is embedded with machine and deep learning algorithms which generate models that can provide accurate solutions for specific biological designs.

Our core technology is called EpitoGen®; a bioengineered recombinant scaffold that can display single or multiple epitopes/antigens, forming the basis of the diagnostic assay.

Both platforms create a self-learning system whereby data generated experimentally is used to train the AI models and improve their predictive accuracy.

Latest news

Learn more about our current projects, the applications of our technology and the company news.